Background
Methods
Search strategy
Inclusion and exclusion criteria
Selection of studies
Data extraction
Definition of outcome events
Quality assessment
Statistical method
Results
Basic characteristics of included studies
Study year | Country | Surgery site | Experimental group | Control group | Prevention method | Study quality | |||||
---|---|---|---|---|---|---|---|---|---|---|---|
n
| Male/female | Age |
n
| Male/female | Age | Experimental group | Control group | ||||
Bi CQ 2009 [12] | China | Fracture and arthroplasty | 35 | 10\25 | 69.57 ± 9.84 | 35 | 7\28 | 66.71 ± 9.13 | On the basis of the control group, Yiqi Poxue traditional Chinese medicine | Low molecular weight heparin (LMWH) | RCT |
Chen CL 2014 [13] | China | Arthroplasty | 48 | 18\30 | 64.5 ± 15.6 | 48 | 12\36 | 61.7 ± 12.5 | On the basis of the control group, Taohong Siwu soup | Rivaroxaban | RCT |
Chen T 2016 [14] | China | Fracture | 45 | 24\21 | 60.6 ± 1.8 | 45 | 25\20 | 60.5 ±2.1 | On the basis of the control group, topical with traditional Chinese medicine | Low molecular weight heparin (LMWH), aspirin | RCT |
Ge XL 2007 [15] | China | Arthroplasty | 30 | – | 66.8 | 30 | – | 66.8 | On the basis of the control group, Ligustrazine hydrochloride | Low molecular weight heparin (LMWH) | RCT |
He Y 2013 [16] | China | Arthroplasty | 62 | – | 64 | 62 | – | 64 | On the basis of the control group, Yiqi Huoxue Huayu soup | Low molecular weight heparin (LMWH) | RCT |
Huang SX 2009 [17] | China | Fracture and arthroplasty | 60 | 35\25 | 58.6 | 60 | 38\22 | 56.2 | On the basis of the control group, Danshen injection liquid | Low molecular weight heparin (LMWH) | RCT |
Huang XG 2010 [18] | China | Arthroplasty | 31 | 11\20 | 58.46 | 32 | 9\23 | 55.72 | On the basis of the control group, Gubu soup | Low molecular weight heparin (LMWH) | RCT |
Jiang KW 2011 [19] | China | Arthroplasty | 65 | – | 66.4 | 73 | – | 66.4 | Chinese medicine decoction | Low molecular weight heparin (LMWH) | RCT |
Li DF 2015 [20] | China | Fracture and arthroplasty | 25 | 16\9 | 22–76 | 25 | 18\7 | 27–77 | On the basis of the control group, Huoxue Tongmai soup | Rivaroxaban | RCT |
Li JH 2015 [21] | China | fracture | 44 | – | 72±17 | 41 | – | 68±18 | Danggui Shaoyao powder | Low molecular weight heparin (LMWH) | RCT |
Lin X 2010 [22] | China | Arthroplasty | 40 | 25\15 | 78.15 ± 15.43 | 40 | 26\14 | 76.36 ± 14.37 | Buyang Huanwu soup | Aspirin | RCT |
Shao ZH 2016 [23] | China | Arthroplasty | 45 | 24\21 | 67.4 ± 5.1 | 45 | 23\22 | 66.6 ± 4.8 | On the basis of the control group, Danshen injection liquid, Taohong Siwu soup | Rivaroxaban | RCT |
Shi M 2011 [24] | China | Arthroplasty | 29 | 22\7 | 69.13 ± 7.89 | 34 | 23\11 | 67.49 ± 8.36 | Chinese medicine decoction | Low molecular weight heparin (LMWH) | RCT |
Wang XG 2017 [25] | China | Fracture and arthroplasty | 34 | 15\19 | 62.6 ± 5.81 | 34 | 16\18 | 63.4 ± 3.17 | On the basis of the control group, Tongmai Yiqi Chinese medicine decoction | Low molecular weight heparin (LMWH) | RCT |
Xiao G 2015 [26] | China | Fracture | 38 | – | – | 38 | – | – | On the basis of the control group, Chinese medicine decoction | Low molecular weight heparin (LMWH) | RCT |
Yuan SH 2009 [27] | China | Arthroplasty | 28 | 16\12 | 66.4 | 26 | 16\10 | 64.5 | On the basis of the control group, Shuxue Tongmai injection liquid | Low molecular weight heparin (LMWH) | RCT |
Zhai JB 2016 [28] | China | Fracture and arthroplasty | 38 | 18\20 | 64.5 ± 10.2 | 38 | 21\17 | 63.1 ± 10.8 | On the basis of the control group, Chinese medicine decoction self-made | Low molecular weight heparin (LMWH) | RCT |
Zhang FY 2009 [29] | China | Fracture and arthroplasty | 45 | 34\11 | 60 | 42 | 30\12 | 56 | On the basis of the control group, Danshen injection liquid | Low molecular weight heparin (LMWH) | RCT |
Zhao Q 2017 [30] | China | Fracture | 95 | 44\51 | 58.94 ± 7.02 | 95 | 47\48 | 58.96 ± 4.93 | On the basis of the control group, Huoxue Zhuyu Tongluo soup | Low molecular weight heparin (LMWH) | RCT |
Zhou ZQ 2010 [31] | China | Fracture and arthroplasty | 73 | 44\29 | 15–85 | 109 | 57\52 | 15–85 | Honghua injection liquid | Low molecular weight heparin (LMWH) | RCT |
First author and year | Traditional Chinese medicine compound | Treatment time | Effect |
---|---|---|---|
Bi CQ 2009 [12] | Huangqi 60 g, shuizhi 5 g, gancao 5 g, sanqi 3 g | Water decoction, po, bid, 7 days | Promoting blood circulation to remove obstruction in the channels |
Chen CL 2014 [13] | Taohong siwu soup:taoren 10 g, honghua 10 g, danggui 12 g, chishuo 10 g, chuangxiong 6 g, dihuang 15 g, chuangshanjia 6 g, chaihu 12 g, huangqi 10 g, xiangfu 12 g, yanhusuo 15 g, xuduan 15 g, gancao 6 g | Water decoction, po, bid, 7 days | Promoting blood by nourishing the blood |
Chen T 2016 [14] | Huajiao, sumu, mugua, shenjincao, danggui, niuxi | Water decoction, hot pack, bid | Promoting blood circulation to relieve pain |
Ge XL 2007 [15] | Yansuan chuanxiong injection 80 mg | ivgit, qd, 10 days | Antiplatelet agglutination, promoting blood circulation to remove obstruction in the channels |
He Y 2013 [16] | Yiqi huoxue huayu soup:dangshen 10 g, fuling 10 g, baishu 10 g, gancao 10 g, honghua 10 g, danggui 10 g, huangqi 10 g, taoren 10 g, shudi 6 g, chuanxiong 6 g, chishuo 6 g, zhike 6 g, jiegeng 6 g, dilong 3 g | Water decoction, po, bid, po, 21 days | Promoting blood circulation to remove obstruction in the channels |
Huang SX 2009 [17] | Danshen injection 20 ml and physiological saline 250 ml | ivgit, qd, 7 days | Promoting blood circulation to remove obstruction in the channels |
Huang XG 2010 [18] | Gubu soup:huangqi 30 g, dangshen 30 g, jixueteng 30 g, danggui 15 g, danshen 30 g, chishuo 15 g, niuxi 15 g, baishu 15 g, yiren 20 g, huangbai 20 g, gancao 10 g | Water decoction, po, bid, po, 9 days | Promoting blood circulation to remove obstruction in the channels |
Jiang KW 2011 [19] | Huangqi 30 g, shuizhi 3 g, sanqi 3 g | Water decoction, po, bid, po, 7 days | Promoting blood circulation to remove obstruction in the channels, pain relief by diminishing swelling |
Li DF 2015 [20] | Huoxue tongmai soup:shuizhi 5 g, honghua 10 g, danggui 10 g, huangqi 20 g, danshen 10 g, fuling 10 g, yanhusuo 8 g, sanqi 6 g | Water decoction, po, bid, po, 7 days | Promoting blood circulation to remove obstruction in the channels |
Li JH 2015 [21] | Danggui shuoyao pills: danggui 3 g, chishuo 16 g, chuanxiong 8 g, fuling 4 g, zhexie 8 g, baishu 4 g | Water pills,5 g/every time, po, qd, 7 days | Promoting blood by nourishing the blood, clearing heat, and removing dampness |
Lin X 2010 [22] | Buyang huanwu soup:sheng huangqi 30 g, dangguiwei 6 g, taoren 6 g, honghua 6 g, chuanxiong 9 g, chishuo 9 g, dilong 3 g, huainiuxi 9 g | Water decoction, po, bid, po, 7 days | Promoting blood circulation to remove obstruction in the channels |
Shao ZH 2016 [23] | Danshen injection 20 ml, and 5% glucose injection; taohong siwu soup:honghua 10 g, taoren 15 g, danggui 15 g, chuanxiong 15 g, chishuoyao 15 g, niuxi 15 g, yinhuateng 20 g, yirenren 15 g, baishu 15 g, fuling 15 g, zhichuanwu 15 g, zhiruxiang 15 g | Danshen injection:ivgit, qd; taohong siwu soup: water decoction, po, bid | Promoting blood by nourishing the blood |
Shi M 2011 [24] | Shenghuangqi, dangguiwei, chishuo, dilong, chuanxiong, taoren, honghua | Water decoction, po, bid, po, 7 days | Promoting blood circulation to remove obstruction in the channels, pain relief by diminishing swelling |
Wang XG 2017 [25] | Tongmaiyiqi soup:huangqi 15 g, baishu 15 g, quanxie 6 g, sanqi 6 g, shuizhi 6 g, zhexie 9 g | Water decoction, po, bid, po, 14 days | Promoting blood circulation to remove obstruction in the channels |
Xiao G 2015 [26] | Huoxue tongmai soup:huangqi 30 g, niuxi 15 g, taoren 15 g, danshen 15 g, chishuo 15 g, shudi 15 g, chuanxiong 10 g, honghua 10 g, dangguiwei 10 g, shuizhi 5 g | Water decoction, po, bid, po, 14 days | Promoting blood by nourishing the blood |
Yuan SH 2009 [27] | Shuxuetong injection 6 ml and 0.9% saline 250 ml | ivgit, qd, 15 days | Promoting blood circulation to remove obstruction in the channels |
Zhai JB 2016 [28] | Chuanxiong 10 g, shuizhi 5 g, honghua 15 g, dangshen 10 g, danggui 5 g, danshen 15 g, niuxi 15 g | Water decoction, po, bid, po, 14 days | Promoting blood circulation to remove obstruction in the channels, pain relief by diminishing swelling |
Zhang FY 2009 [29] | Danshen injection 20 ml | IV, qd, 7 days | Promoting blood circulation to remove obstruction in the channels |
Zhao Q 2017 [30] | Huoxue zhuyu tongluo soup:dangguo 20 g, yirenren 5 g, danshen 10 g, shangzhi 5 g, tubie 5 g, sumu 10 g, chuanxiong 20 g, niuxi 3 g | Water decoction, po, bid, po, 14 days | Promoting blood circulation to relieve pain |
Zhou ZQ 201031 | Honghua injection 20 ml and 0.9% saline 250 ml | ivgit, qd, 10 days | Promoting blood circulation to remove obstruction in the channels |
First author and year | DVT diagnosis | Experimental group | Control group | DVT site |
---|---|---|---|---|
Bi CQ 2009 [12] | Color Doppler ultrasound | 0/35 (0.00%) | 1/35 (2.86%) | Not mentioned |
Chen CL 2014 [13] | Not mentioned | 1/48 (2.1%) | 4/48 8.3% | Not mentioned |
Chen T 2016 [14] | Not mentioned | 2/45 (4.44%) | 15/45 (33.33%) | Not mentioned |
Ge XL 2007 [15] | Color Doppler ultrasound, Angiography | 0/30 (0%) | 2/30 (6.67%) | Distal thrombosis of the lower limbs |
He Y 2013 [16] | Color Doppler ultrasound | 5/62 (8.1%) | 7/62 (11.3%) | Not mentioned |
Huang SX 2009 [17] | Color Doppler ultrasound | 2/60 (3.3%) | 12/60 (20%) | Not mentioned |
Huang XG 2010 [18] | Color Doppler ultrasound | 4/31(12.9%) | 7/32 (21.9%) | Popliteal vein thrombosis 3 case, calf venous plexus 8 case |
Jiang KW 2011 [19] | Color Doppler ultrasound, Angiography | 12/65 (18%) | 8/73 (11%) | Femoral vein thrombosis 1 case, popliteal vein thrombosis 1 case, gastrocnemius thrombosis 18 case |
Li DF 2015 [20] | Not mentioned | 2/25 (8.0%) | 4/25 (16.0%) | Not mentioned |
Li JH 2015 [21] | Color Doppler ultrasound | 1/44 (2.3%) | 6/41 (14.6%) | Not mentioned |
Lin X 2010 [22] | Color Doppler ultrasound | 4/40 (10.0%) | 10/40 (25.0%) | Not mentioned |
Shao ZH 2016 [23] | Color Doppler ultrasound | 1/45 (2.0%) | 6/45 (13.0%) | Lower limb femoral vein |
Shi M 2011 [24] | Color Doppler ultrasound | 0/29 (0%) | 0/34 (0%) | Lower limb femoral vein |
Wang XG 2017 [25] | Color Doppler ultrasound | 1/34 (2.94%) | 2/34 (5.88%) | Not mentioned |
Xiao G 2015 [26] | Not mentioned | 0/38 (0%) | 4/38 (10.53%) | Not mentioned |
Yuan SH 2009 [27] | Color Doppler ultrasound | 1/28 (3.57%) | 6/26 (23.07%) | Not mentioned |
Zhai JB 2016 [28] | Color Doppler ultrasound | 1/38(2.6%) | 6/38 (15.8%) | Not mentioned |
Zhang FY 2009 [29] | Color Doppler ultrasound | 4/45 (8.9%) | 7/42 (16.7%) | Femoral vein thrombosis 7 case, popliteal vein thrombosis 4 case |
Zhao Q 2017 [30] | Color Doppler ultrasound | 9/95 (9.5%) | 26/95 (27.4%) | Not mentioned |
Zhou ZQ 2010 [31] | Color Doppler ultrasound | 5/73 (6.8%) | 11/109 (10.1%) | Not mentioned |
First author and year | PT | APTT | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Experimental group | Control group | Experimental group | Control group | |||||||||
n
| Before the drug | After the drug |
n
| Before the drug | After the drug | Before the drug |
n
| After the drug |
n
| Before the drug | After the drug | |
He Y 2013 [16] | 62 | 14.322 ± 0.968 | 13.492 ± 0.892 | 62 | 14.102 ± 1.132 | 13.321 ± 1.211 | 38.902 ± 5.232 | 62 | 40.024 ± 6.211 | 62 | 40.101 ± 6.403 | 40.883 ± 5.862 |
Jiang KW 2011 [19] | 65 | 14.248 ± 0.987 | 13.440 ± 0.795 | 73 | 14.037 ± 1.250 | 13.277 ± 1.661 | 38.862 ± 6.015 | 65 | 38.271 ± 3.915 | 73 | 41.797 ± 7.333 | 41.171 ± 6.741 |
Shao ZH 2016 [23] | 45 | 11.30 ± 1.65 | 12.65 ± 1.56 | 45 | 11.28 ± 1.57 | 13.43 ± 1.38 | 30.99 ± 4.63 | 45 | 34.05 ± 4.92 | 45 | 31.23 ± 4.38 | 39.21 ± 5.28 |
Shi M 2011 [24] | 29 | 13.504 ± 0.857 | 13.925 ± 1.143 | 34 | 13.421 ± 1.009 | 13.863 ± 0.976 | 36.982 ± 4.526 | 29 | 36.334 ± 5.613 | 34 | 37.753 ± 6.667 | 36.826 ± 4.761 |
Wang XG 2017 [25] | 34 | 14.17 ± 0.74 | 13.37 ± 0.83 | 34 | 14.26 ± 0.88 | 13.92 ± 0.59 | 37.99 ± 8.02 | 34 | 35.91 ± 6.95 | 34 | 37.25 ± 6.44 | 36.19 ± 7.93 |
Xiao G 2015 [26] | 38 | 13.47 ± 1.26 | 11.84 ± 0.63 | 38 | 13.56 ± 1.53 | 12.73 ± 1.42 | 31.06 ± 5.87 | 38 | 26.15 ± 4.18 | 38 | 31.52 ± 6.08 | 29.33 ± 5.27 |
Zhao Q 2017 [30] | 95 | 10.08 ± 0.89 | 14.98 ± 2.04 | 95 | 10.06 ± 1.04 | 12.72 ± 2.07 | 20.14 ± 3.79 | 95 | 37.89 ± 2.95 | 95 | 20.56 ± 3.80 | 29.69 ± 3.17 |
Zhou ZQ 2010 [31] | 73 | 12.54 ± 1.04 | 12.55 ± 1.4 | 109 | 12.86 ± 1.18 | 12.85 ± 1.41 | 36.64 ± 4.35 | 73 | 36.79 ± 4.61 | 109 | 37.65 ± 5.56 | 38.01 ± 5.67 |
First author and year | Experimental group | Control group | ||||
---|---|---|---|---|---|---|
Before the drug |
n
| After the drug |
n
| Before the drug | After the drug | |
Bi CQ 2009 [12] | 1.12 ± 1.11033 | 35 | 0.6829 ± 0.4547 | 35 | 0.74 ± 0.90365 | 0.72 ± 0.53292 |
He Y 2013 [16] | 1.242 ± 1.078 | 62 | 0.792 ± 0.592 | 62 | 0.832 ± 0.912 | 0.792 ± 0.612 |
Jiang KW 2011 [19] | 1.120 ± 1.110 | 65 | 0.682 ± 0.454 | 73 | 0.740 ± 0.903 | 0.720 ± 0.532 |
Li JH 2015 [21] | 0.856 ± 0.187 | 44 | 0.509 ± 0.284 | 41 | 0.791 ± 0.221 | 0.693 ± 0.457 |
Shao ZH 2016 [23] | 0.154 ± 0.060 | 45 | 1.405 ± 0.362 | 45 | 0.142 ± 0.051 | 1.968 ± 0.527 |
Shi M 2011 [24] | 0.986 ± 0.325 | 29 | 0.603 ± 0.428 | 34 | 0.962 ± 0.547 | 0.891 ± 0.734 |
Xiao G 2015 [26] | 0.16 ± 0.09 | 38 | 0.11 ± 0.26 | 38 | 0.17 ± 0.10 | 0.16 ± 0.11 |
Zhai JB 2016 [28] | 1.525 ± 0.347 | 38 | 1.642 ± 0.389 | 38 | 1.493 ± 0.321 | 2.205 ± 0.561 |
Zhao Q 2017 [30] | 1.90 ± 0.43 | 95 | 1.65 ± 0.56 | 95 | 1.90 ± 0.40 | 1.62 ± 0.62 |
First author and year | Subcutaneous hematoma | |
---|---|---|
Experimental group | Control group | |
Bi CQ 2009 [12] | 10/35 (28.57%) | 26/35 (74.29%) |
Jiang KW 2011 [19] | 1/65 (2.2%) | 8/73 (17.8%) |
Li DF 2015 [20] | 4/25 (8.9%) | 11/25 (44.0%) |
Li JH 2015 [21] | 2/44 (4.5%) | 1/41 (2.4%) |